TapewireFind a company

person · Reporting owner

Islam Khalid

Disclosed activity across 4 companies

Tapewire entity
29907
SEC CIK
0001701858

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
FENNEC PHARMACEUTICALS INC.FENC · Entity 5601DirectorJune 10, 2026June 10, 2026
Gain Therapeutics, Inc.GANX · Entity 6943DirectorJuly 15, 2026July 17, 2026
Processa Pharmaceuticals, Inc.PCSA · Entity 8210DirectorMarch 15, 2022April 20, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FENNEC PHARMACEUTICALS INC.

Report date June 10, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2036-06-10Direct250,000 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Grant · Acquired 25,000 · Balance 250,000

F1: On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2: The option is 100% vested on date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2: The option is 100% vested on date of grant.

Gain Therapeutics, Inc.

Report date July 15, 2026 · Filed July 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15Direct25,000 Reported balance After 2026-07-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000

F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Processa Pharmaceuticals, Inc.

Report date March 15, 2022 · Filed April 20, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct18,208 Reported balance After 2022-01-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-01-01 · Grant · Acquired 18,208 · Balance 18,208

F1: Restricted stock units vest 100% on December 31, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units vest 100% on December 31, 2022.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IMMUNOMEDICS INC

Report date October 23, 2020 · Filed October 23, 2020

Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-10-23 transaction · row 1
1 source row

Row 1 · 2020-10-23 · Disposition to issuer · Disposed 13,516 · Balance 0

F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-10-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-10-23 · Disposition to issuer · Disposed 52,614 · Balance 0

F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-10-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0

F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 15, 2026 Filed Jul 17, 2026 12:32 UTC Gain Therapeutics, Inc. GANX · Entity 6943 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001104659-26-084437 · tm2620629-4_4seq1.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-07-15

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Read SEC document
June 10, 2026 Filed Jun 10, 2026 21:26 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option · Derivative 25,000 $8.70 Strike: $8.70 $217,500.00
Disclosure

SEC source: 0001701858-26-000002 · form4-06102026_090631.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Shares · 25,000 shares

Expires 2036-06-10

F1 · security: On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested on date of grant.

Read SEC document
June 24, 2025 Filed Jun 25, 2025 21:30 UTC Gain Therapeutics, Inc. GANX · Entity 6943 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $1.79 $0.00
Disclosure

SEC source: 0001641172-25-016541 · ownership.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date.

Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:20 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option · Derivative 25,000 $7.88 Strike: $7.88 $197,000.00
Disclosure

SEC source: 0001415889-25-015586 · form4-06042025_040601.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Shares · 25,000 shares

Expires 2035-06-03

F1 · security: On June 3, 2025, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested on date of grant.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 23:02 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option · Derivative 25,000 $5.58 Strike: $5.58 $139,500.00
Disclosure

SEC source: 0001415889-24-021641 · form4-08192024_110810.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Shares · 25,000 shares

Expires 2034-08-15

F1 · security: On August 15, 2024, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested of date of grant.

Read SEC document
August 09, 2024 Filed Aug 12, 2024 21:23 UTC Gain Therapeutics, Inc. GANX · Entity 6943 PurchaseCommon Stock 50,000 $1.00 $49,940.00
Disclosure

SEC source: 0001493152-24-031377 · ownership.xml · nonDerivative · entry 2

Islam Khalid · CIK 0001701858 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Read SEC document
June 24, 2024 Filed Jun 27, 2024 01:30 UTC Gain Therapeutics, Inc. GANX · Entity 6943 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $1.29 $0.00
Disclosure

SEC source: 0001493152-24-025342 · ownership.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-06-24

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares · Derivative 20,492 $2.44 Strike: $2.44 $50,000.48
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · derivative · entry 8

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Options · 20,492 shares

Expires 2026-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Represents options granted on June 9, 2016, with a strike price of $2.44 and an expiration date of June 9, 2026.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares · Derivative 50,000 $1.13 Strike: $1.13 $56,500.00
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · derivative · entry 7

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,492

Underlying: Options · 50,000 shares

Expires 2025-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Represents options granted on December 11, 2015, with a strike price of $1.13 and an expiration date of December 11, 2025.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares · Derivative 10,000 $2.69 Strike: $2.69 $26,900.00
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · derivative · entry 6

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,492

Underlying: Options · 10,000 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Represents options granted on December 31, 2014, with a strike price of $2.69 and an expiration date of December 31, 2024.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares · Derivative 133,333 $2.31 Strike: $2.31 $307,999.23
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · derivative · entry 5

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,492

Underlying: Options · 133,333 shares

Expires 2024-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Represents options granted on April 25, 2014, with a strike price of $2.31 and an expiration date of April 25, 2024.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares 20,492 $2.44 $50,000.48
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · nonDerivative · entry 4

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Shares acquired through the exercise of an option contract with a strike of $2.44 and an expiration date of June 9, 2026.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares 50,000 $1.13 $56,500.00
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · nonDerivative · entry 3

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Shares acquired through the exercise of an option contract with a strike of $1.13 and an expiration date of December 11, 2025.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares 10,000 $2.69 $26,900.00
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · nonDerivative · entry 2

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Shares acquired through the exercise of an option contract with a strike of $2.69 and an expiration date of December 31, 2024.

Read SEC document
November 16, 2023 Filed Nov 16, 2023 21:05 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 Exercise / conversionCommon Shares 133,333 $2.31 $307,999.23
Disclosure

SEC source: 0001415889-23-015193 · form4-11162023_091111.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Shares acquired through the exercise of an option contract with a strike of $2.31 and an expiration date of April 25, 2024.

Read SEC document
June 23, 2023 Filed Jun 26, 2023 20:40 UTC Gain Therapeutics, Inc. GANX · Entity 6943 GrantStock Option (right to buy) · Derivative 10,500 $0.00 Strike: $4.50 $0.00
Disclosure

SEC source: 0001209191-23-039726 · doc4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires 2033-06-23

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date.

Read SEC document
June 12, 2023 Filed Jun 13, 2023 16:39 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option · Derivative 25,000 $0.00 Strike: $8.78 $0.00
Disclosure

SEC source: 0001415889-23-009706 · form4-06132023_040647.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,825

Underlying: Common Shares · 25,000 shares

Expires 2033-06-12

F1 · security: On June 12, 2023, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested of date of grant.

Read SEC document
September 20, 2022 Filed Sep 22, 2022 20:13 UTC Gain Therapeutics, Inc. GANX · Entity 6943 GrantStock Option (right to buy) · Derivative 10,500 $0.00 Strike: $3.50 $0.00
Disclosure

SEC source: 0001209191-22-051012 · doc4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires 2032-09-20

F1 · derivative.exercise_date: The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
June 14, 2022 Filed Jun 16, 2022 13:24 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $5.59 $0.00
Disclosure

SEC source: 0001104659-22-071689 · tm2218610-4_4seq1.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2032-06-14

F1 · security: On June 14, 2022, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested on the date of grant.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:57 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 4,392 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-008012 · doc1.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,486

F1 · price: Vesting of time-based restricted shares.

F2 · balance_after: Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in a transaction exempt from Section 16 reporting pursuant to Rule 16a-13.

Read SEC document
January 01, 2022 Filed Apr 20, 2022 01:15 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock · Derivative 18,208 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008682 · doc1.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,208

Underlying: Common Stock · 18,208 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted stock units vest 100% on December 31, 2022.

F1 · derivative.expiration_date: Restricted stock units vest 100% on December 31, 2022.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 17:00 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $7.52 $0.00
Disclosure

SEC source: 0001104659-21-088127 · tm2121155-4_4seq1.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2031-06-29

F1 · security: On June 29, 2021, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested on the date of grant.

Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:33 UTC IMMUNOMEDICS INC IMMU · Entity 145732 Disposition to issuerRestricted Stock Unit · Derivative 3,718 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-117797 · a4.xml · derivative · entry 3

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,718 shares

Expires not disclosed

F3 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

F3 · price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

F3 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

F3 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:33 UTC IMMUNOMEDICS INC IMMU · Entity 145732 Disposition to issuerStock Option (Right to Buy) · Derivative 52,614 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-117797 · a4.xml · derivative · entry 2

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 52,614 shares

Expires not disclosed

F2 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F2 · price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F2 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F2 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:33 UTC IMMUNOMEDICS INC IMMU · Entity 145732 Disposition to issuerCommon Stock 13,516 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-117797 · a4.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

F1 · price: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

Read SEC document
August 13, 2020 Filed Aug 14, 2020 19:17 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $6.17 $0.00
Disclosure

SEC source: 0001104659-20-095448 · tm2027709d4_4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2030-08-13

F1 · security: On August 13, 2020, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan.

F2 · derivative.exercise_date: The option is 100% vested on the date of grant.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:20 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantStock Option (right to buy) · Derivative 6,540 $0.00 Strike: $33.62 $0.00
Disclosure

SEC source: 0001104659-20-075695 · a4.xml · derivative · entry 2

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,540

Underlying: Common Stock, par value $0.01 per share · 6,540 shares

Expires 2030-06-18

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020.

F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:20 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantCommon Stock, $0.01 par value per share 3,718 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-075695 · a4.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,234

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020.

F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
June 18, 2019 Filed Jun 20, 2019 00:33 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $4.26 $0.00
Disclosure

SEC source: 0001144204-19-031564 · tv523893_4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2029-06-18

F1 · security: On June 18, 2019, Khalid Islam was granted an incentive stock option to purchase 25,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan.

F2 · derivative.exercise_date: The option is 100% vested on the date of grant.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 16:32 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantStock Option (right to buy) · Derivative 17,077 $0.00 Strike: $12.93 $0.00
Disclosure

SEC source: 0001104659-19-034792 · a4.xml · derivative · entry 2

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,077

Underlying: Common Stock, par value $0.01 per share · 17,077 shares

Expires 2026-06-07

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019.

F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 16:32 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantCommon Stock, $0.01 par value per share 9,667 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-034792 · a4.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,516

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019.

F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 14:44 UTC FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $10.93 $0.00
Disclosure

SEC source: 0001144204-18-033681 · tv496273_4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2025-06-08

F1 · security: On June 8, 2018, Khalid Islam was granted an incentive stock option to purchase 25,000 common shares of the Issuer pursuant to the Issuer's Amended and Restated Stock Option Plan. The option is 100% vested on the date of grant.

Read SEC document
April 02, 2018 Filed Sep 19, 2018 15:21 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantStock Options (right to buy) · Derivative 6,497 $0.00 Strike: $14.29 $0.00
Disclosure

SEC source: 0001171843-18-006626 · ownership.xml · derivative · entry 2

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,497

Underlying: Common Stock, par value $0.01 per share · 6,497 shares

Expires 2025-04-02

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018.

F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
April 02, 2018 Filed Sep 19, 2018 15:21 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantCommon Stock, $0.01 par value per share 3,849 $0.00 $0.00
Disclosure

SEC source: 0001171843-18-006626 · ownership.xml · nonDerivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,849

F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018.

F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.

Read SEC document
July 03, 2017 Filed Jul 6, 2017 18:01 UTC IMMUNOMEDICS INC IMMU · Entity 145732 GrantStock Options (right to buy) · Derivative 22,500 $0.00 Strike: $9.02 $0.00
Disclosure

SEC source: 0001104659-17-043897 · a4.xml · derivative · entry 1

Islam Khalid · CIK 0001701858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock, par value $0.01 per share · 22,500 shares

Expires 2024-07-03

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.